OVDs ideal for microincision surgery

Article

Moderately cohesive ophthalmic viscosurgical devices offer desired performance traits

She presented findings from a study evaluating the OVD behaviour and endothelial cell loss in groups of 20 eyes each operated on using PhysioVisc Integral (PhysIOL, Liège, Belgium), Amvisc Plus (Bausch + Lomb Surgical, Greater London, UK) or Z-Hyalin Plus (Carl Zeiss Meditec, Jena, Germany). All surgeries were performed using the same phacoemulsification platform (Stellaris, Bausch + Lomb) and a bimanual microincision technique involving two 1.2 mm incisions and with enlargement of one incision to 1.7 mm for IOL implantation.

Observations

"When surgeons perform cataract surgery through self-sealing incisions, the OVD is expected to maintain the anterior chamber depth so as to facilitate the capsulorhexis," she explained. "However, while the OVD needs to provide space and tissue protection, if it is not spontaneously expelled during surgical manoeuvers, particularly during hydrodissection, there is a risk of overpressurisation that can lead to capsule rupture.

"The study results show that each of these OVDs offers behaviour that is in line with [the] surgeon's expectations and that the OVDs provided good protection for the corneal endothelium," Dr Deidier added.

As moderately cohesive OVDs, all three products evaluated in the study have high viscosity, strong elasticity and strong pseudoplasticity that allow easy injection through a 27-gauge cannula and removal at the end of the procedure, even with 1.2 mm microincision instruments, noted Dr Deidier.

The three study groups were similar with respect to mean patient age (72 to 76 years), cataract grade (about LOCS III) and preoperative ECC measured by specular microscopy (about 2400 cells/mm2). Based on measurements performed at a month after surgery, mean ECC loss was 1% in eyes operated on with PhysioVisc Integral, 1.09% in the Amvisc Plus group and 1.01% for the Z-Hyalin Plus procedures.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.